Companies › ARS Pharmaceuticals
2 active drug programs in 12 registered trials: 5 Phase 2, 3 Phase 4, 3 Phase 3, 1 Phase 1; Immunology, Cardiovascular, Genitourinary, Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Epinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Allergic Reactions; Knee Arthroplasty, Total; Cardiac Arrest, Out-Of-Hospital; Shock Hypovolemic … | Apr 2027 |
| ARS-2 | – | Phase 2 | Urticaria Chronic | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06456255 | Epinephrine | Phase 2 | Sinus Disease | Other | May 2025 |
| NCT04750070 | Epinephrine | Phase 3 | Shock Hypovolemic | Genitourinary | Jul 2025 |
| NCT06920173 | Epinephrine | Phase 2 | Shock | Other | Dec 2025 |
| NCT07733167 | Epinephrine | Phase 3 | Intra-Prostatic Epinephrine Injection in Bipolar Transurethral Resection of Large Prostate | Psychiatry | Mar 2026 |
| NCT06847568 | Epinephrine | Phase 3 | ST Segment Elevation Myocardial Infarction (STEMI) | Cardiovascular | Apr 2026 |
| NCT07038746 | Epinephrine | Phase 1 | Hypersensitivity | Other | Dec 2026 |
| NCT06834165 | Epinephrine | Phase 4 | Allergic Reactions | Immunology | Apr 2027 |
| NCT06927999 | ARS-2 | Phase 2 | Urticaria Chronic | Immunology | Jun 2027 |
| NCT07089251 | Epinephrine | Phase 4 | Knee Arthroplasty, Total | Immunology | Jun 2027 |
| NCT05166343 | Epinephrine | Phase 2 | Pediatric Out-of-Hospital Cardiac Arrest | Cardiovascular | Jan 2028 |
| NCT03826524 | Epinephrine | Phase 4 | Cardiac Arrest, Out-Of-Hospital | Cardiovascular | Dec 2028 |
| NCT07392580 | Epinephrine | Phase 2 | Laryngeal Squamous Cell Carcinoma | Oncology | Sep 2031 |
Cash and short-term investments of $138m on 2026-09-30; operating cash outflow about $187m a year; runway about 9 months at that burn, to Jun 2027; 1 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Acer Therapeutics Santen SAS Chiesi Farmaceutici AstraZeneca Opus Genetics Guangzhou Novaken Pharm BioXcel Therapeutics Teikoku Pharma USA Tecnoquimicas Tarian Pharma
Acer Therapeutics Tarian Pharma Karyopharm Therapeutics Enlivex Therapeutics Arthrosi Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.